HTA Implementation Roadmap in Central and Eastern European Countries

Health Economics (United Kingdom)

Volumn 25, Issue , 2016, Pages 179-192

  Kaló, Zoltán ^a,b   Gheorghe, Adrian ^c   Huic, Mirjana ^d   Csanádi, Marcell ^b   Kristensen, Finn Boerlum ^e,f  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b Syreon Research Institute   (Hungary)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Agency for Quality and Accreditation in Health   (Croatia)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f Danish Health and Medicines Authority   (Denmark)

Author keywords

Central and Eastern European countries; economic evaluation; evidence based decision making; health technology assessment; HTA components; HTA implementation

Indexed keywords

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CULTURAL ANTHROPOLOGY; DATA PROCESSING; DECISION MAKING; EASTERN EUROPE; FINANCIAL MANAGEMENT; HEALTH CARE CONCEPTS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; METHODOLOGY; ORGANIZATIONAL STRUCTURE; POLITICAL PARTICIPATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIAL STATUS; STANDARDIZATION; CAPACITY BUILDING; COST BENEFIT ANALYSIS; ECONOMICS; EUROPE; HUMAN; ORGANIZATION AND MANAGEMENT; RESOURCE ALLOCATION;

CAPACITY BUILDING; COST-BENEFIT ANALYSIS; EUROPE; HEALTH POLICY; HUMANS; RESOURCE ALLOCATION; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84956580438     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.3298     Document Type: Article

References (59)

1. Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Parent F, Piccart M,. 2014. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the Trastuzumab case. European Journal of Cancer 50 (18): 3089-3097.
2. Allen N, Pichler F, Wang T, Patel S, Salek S,. 2013. Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems. Health Policy 113: 305-312.
3. Artells JJ, Peiro S, Meneu R,. 2014. Barreras a la introducción de una agencia evaluadora para informar la financiación o la desinversión de prestaciones sanitarias del Sistema Nacional de Salud [Barriers for Introducing a Health Technology Assessment Organization to Inform Health Care Decision-Making in the Spanish National Health System]. Revista Española de Salud Pública 88: 2 Madrid Mar.-Apr.
4. Boncz I, Vajda R, Ágoston I, Endrei D, Sebestyén A,. 2014. Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010. The European Journal of Health Economics (Suppl 1): S137-S141.
5. Carone G, Schwierz C, Xavier A,. 2012. Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers 461. European Commission, Available at http://ec.europa.eu/economy-finance/publications/economic-paper/2012/pdf/ecp-461-en.pdf (accessed December 2014)
6. Danguole J,. 2009. Development of health technology assessment in Lithuania. International Journal of Technology Assessment in Health Care 25: 140-142.
7. Drummond MF, Schwartz JS, Jonsson B, et al,. 2008. Key principles for the improved conduct of health technology assessment for resource allocation decisions. International Journal of Technology Assessment in Health Care 24: 244-258.
8. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J,. 2009. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value in Health 12: 409-418.
9. Economic Reforms (Transition to a Market-Based Economy), European Transition Compendium, European Commission, Available at https://webgate.ec.europa.eu/multisite/etc./en/content/economic-reforms-transition-market-based-economy (accessed January 2015)
10. Endrei D, Molics B, Agoston I,. 2014. Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary. Value in Health 17 (4): 487-489.
11. Gerhardus A, Dorendorf E, Rottingen JA, Santamera AS,. 2008. What are the effects of HTA reports on the health system? Evidence from the research literature. In Verdasco-Garrido M, Kristensen FB, Nielsen Palmhoj C, Busse R. Health Technology Assessment and health policy-making in Europe-Current status, challenges and potential. WHO on behalf of the European Observatory on Health Systems and Policies. http://www.euro.who.int/--data/assets/pdf-file/0003/90426/E91922.pdf (accessed December 2014)
12. Gibis B, Artiles J, Corabian P, Meiesaar K, Koppel A, Jacobs P, Serrano P, Menon D,. 2001. Application of strengths, weaknesses, opportunities and threats analysis in the development of a health technology assessment program. Health Policy 58: 27-35.
13. Grutters JP, Seferina SC, Tjan-Heijnen VC, van Kampen RJ, Goettsch WG, Joore MA,. 2011. Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions. Value in Health 14 (5): 777-784.
14. Grzywacz K, Pelczarska A, Witkowski MA, Ofierska-Sujkowska G, Zawada A,. 2014. The cost-effectiveness threshold for orphan designations in Poland based on reimbursement decisions. Value in Health 17 (7): A450.
15. Gulácsi L, Rotar AM, Niewada M, Löblová O, Rencz F, Petrova G, Boncz I, Klazinga NS,. 2014. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. European Journal of Health Economics 15: S13-S25.
16. Henshall C,. 2012. Using health technology assessment to support optimal use of technologies in current practice: the challenge of "disinvestment". International Journal of Technology Assessment in Health Care 28 (3): 203-210.
17. Hoomans T, Severens JL,. 2014. Economic evaluation of implementation strategies in health care. Implementation Science 9 (1): 168.
18. Huic M,. 2011. Procjena zdravstvenih tehnologija u Hrvatskoj: uloga Agencije za kvalitetu i akreditaciju u zdravstvu. [Article in Croatian] HČJZ. 7: e
19. Huic M, Nachtnebel A, Zechmeister I, Pasternak I, Wild C,. 2013. Collaboration in health technology assessment (EUnetHTA joint action, 2010-2012): four case studies. International Journal of Technology Assessment in Health Care 12: 1-8.
20. INAHTA. 2014. HTA tools and resources. Available at http://www.inahta.org/hta-tools-resources/ (accessed December 2014)
21. Innvaer S, Vist G, Trommald M, Oxman A,. 2002. Health policy-makers' perceptions of their use of evidence: a systematic review. Journal of Health Services Research & Policy 7 (4): 239-244.
22. Inotai A, Pékli M, Jóna G, Nagy O, Remák E, Kaló Z,. 2012. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. BMC Health Services Research 12: 332.
23. Iskrov G, Miteva-Katrandzhieva T, Stefanov R,. 2012. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria. Health Policy 108: 10-18.
24. Iskrov GG, Raycheva RD, Stefanov RS,. 2013. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs. Folia Medica 55: 80-86.
25. Jakovljevic MB,. 2013. Resource allocation strategies in Southeastern European health policy. European Journal of Health Economics 14: 153-159.
26. Kaló Z, Bodrogi J, Boncz I, Cs D, Jóna G, Kövi R, Zs P, Sinkovits B,. 2013. Capacity building for HTA implementation in middle-income countries: the case of Hungary. Value in Health Regional Issues 2: 264-266.
27. Kaló Z, Landa K, Dolezal T, Vokó Z,. 2012. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. European Journal of Cancer Care 21: 442-449.
28. Kolasa K, Kalo Z, Zah V, Dolezal T,. 2012. Role of health technology assessment in the process of implementation of the EU transparency directive: relevant experience from Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research 12 (3): 283-287.
29. Kolasa K, Schubert S, Manca A, Hermanowski T,. 2011. A review of health technology assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy 102: 145-151.
30. Kolasa K, Wasiak R,. 2012. Health technology assessment in Poland and Scotland: comparison of process and decisions. International Journal of Technology Assessment in Health Care 28: 70-76.
31. Kristensen FB, Gerhardus A,. 2010. Health technology assessments: what do differing conclusions tell us? BMJ 341: c5236.
32. Kristensen FB, Lampe K, Chase DL, et al,. 2009. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European network for health technology assessment, EUnetHTA. International Journal of Technology Assessment in Health Care 25 (Suppl 2): 1-8.
33. Liverani M, Hawkins B, Parkhurst JO,. 2013. Political and institutional influences on the use of evidence in public health policy. A systematic review. PLoS ONE 8: 10.
34. Lopert R, Ruiz F, Chalkidou K,. 2013. Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania. Health Policy 112: 202-208.
35. Mathew JL,. 2011. KNOW ESSENTIALS: a tool for informed decisions in the absence of formal HTA systems. International Journal of Technology Assessment in Health Care 27 (2): 139-150.
36. Mittermayer R, Huic M, Mestrovic J,. 2010. Quality of health care, accreditation, and health technology assessment in Croatia: role of Agency for Quality and Accreditation in Health. Acta Medica Croatica 64 (5): 425-434.
37. Muratov S, Juzwishin D, Hailey D, La Fleur P, Foerster V, McGowan J, Brady B,. 2014. Mentoring a health technology assessment initiative in Kazakhstan. International Journal of Technology Assessment in Health Care 30 (2): 1-6.
38. Neumann PJ, Weinstein MC,. 2010. Legislating against use of cost-effectiveness information. The New England Journal of Medicine 363: 1495-1497.
39. Nicod E, Kanavos P,. 2012. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Health Policy 108: 167-177.
40. Nizankowski R, Wilk N,. 2009. From idealistic rookies to a regional leader: the history of health technology assessment in Poland. International Journal of Technology Assessment in Health Care 25: 156-162.
41. Oliver K, Innvar S, Lorenc T, Woodman J, Thomas J,. 2014. A systematic review of barriers to and facilitators of the use of evidence by policymakers. BMC Health Services Research 14: 2.
42. Oortwijn W, Broos P, Vondeling H, Banta D, Todorova L,. 2013. Mapping of health technology assessment in selected countries. International Journal of Technology Assessment in Health Care 29 (4): 424-434.
43. Ozieramski P, McKee M, King L,. 2012a. Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? Health Economics, Policy, and Law 7 (2): 175-195.
44. Ozieranski P, McKee M, King L,. 2012b. The politics of health technology assessment in Poland. Health Policy 108: 178-193.
45. Péntek M, Gy P, Wiland P, Olejárová M, Brzosko M, Codreanu C, Brodszky N, Gulácsi L,. 2014. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. European Journal Health Economics 15 (1): 35-43.
46. Rechel B, Blackburn CM, Spencer NJ, Rechel B,. 2009. Access to health care for Roma children in Central and Eastern Europe: findings from a qualitative study in Bulgaria. International Journal of Equity in Health 8: 24.
47. Rudmik L, Drummond M,. 2013. Health economic evaluation: important principles and methodology. Laryngoscope 123 (6): 1341-1347.
48. Skoupá J, Annemans L, Hájek P,. 2014. Health economic data requirements and availability in the European Union: results of a survey among 10 European countries. Value in Health Regional Issues 4C: 53-57.
49. Stafinski T, Menon D, Davis C, McCabe C,. 2011. Role of centralized review processes for making reimbursement decisions on new health technologies in Europe. ClinicoEconomics and Outcomes Research 3: 117-186.
50. Szegedi M, Molnár MJ, Boncz I, Kosztolányi G,. 2014. Focus shifts in the Hungarian reimbursement system. Funding of orphan medicinal products for rare disease patients in Hungary: financing of orphan medicines. [Article in Hungarian]. Orvosi Hetilap 1. 155. 44.: 1735-1741.
51. ten Have A, Oortwijn W, Broos P, Nelissen E,. 2013. European cooperation on health technology assessment-economic and governance analysis of the establishment of a permanent secretariat. http://ec.europa.eu/health/technology-assessment/docs/study-ecorys-european-cooperation-hta-en.pdf (accessed December 2014)
52. Tesar T,. 2012. Health technology assessment in reimbursement policy of the Slovak Republic. Journal of Health Policy and Outcomes Research 1: 21-23.
53. Tunis SR, Turkelson C,. 2012. Using health technology assessment to identify gaps in evidence and inform study design for comparative effectiveness research. Journal of Clinical Oncology 30: 34.
54. Turk E, Albreht T, Rupel VP,. 2010. The institutionalisation of health technology assessment in Slovenia. Eurohealth 16: 2.
55. Velasco-Garrido M, Busse R,. 2005. Health technology assessment-An introduction of objectives, role of evidence, and structure in Europe. European Observatory on Health Systems and Policies. http://www.euro.who.int/--data/assets/pdf-file/0018/90432/E87866.pdf (accessed December 2014)
56. Welte R, Feenstra F, Jager H, Leidl RA,. 2004. Decision chart for assessing and improving the transferability of economic evaluation results between countries. PharmacoEconomics 22: 857-876.
57. Vladescu C, Baculea S, Chiriac N,. 2009. The burden of cancer and market access for new oncology drugs in European countries. Management in Health.
58. Woodford GE, Cook A,. 2014. European network for health technology assessment joint action (EUnetHTA JA): a process evaluation performed by questionnaires and documentary analysis. Health Technology Assessment 18 (37): 1-296.
59. Zah V,. 2011. The role of health technology assessment in reimbursement policy-experiences from the Republic of Serbia. IME 10 (9): 42-44.